Ensysce Biosciences, Inc.
ENSC
$0.47
$0.000.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.16M | 961.00K | 1.88M | 493.10K | 1.37M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.16M | 961.00K | 1.88M | 493.10K | 1.37M |
| Cost of Revenue | 2.47M | 3.35M | 3.61M | 2.95M | 1.92M |
| Gross Profit | -1.31M | -2.39M | -1.73M | -2.46M | -552.00K |
| SG&A Expenses | 1.27M | 1.18M | 1.05M | 1.28M | 1.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.74M | 4.52M | 4.66M | 4.23M | 3.12M |
| Operating Income | -2.58M | -3.56M | -2.78M | -3.74M | -1.75M |
| Income Before Tax | -2.57M | -3.56M | -2.77M | -3.73M | -1.73M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.57M | -3.56M | -2.77M | -3.73M | -1.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 200.00 | -- | 300.00 | -- | 200.00 |
| Net Income | -2.57M | -3.56M | -2.77M | -3.73M | -1.73M |
| EBIT | -2.58M | -3.56M | -2.78M | -3.74M | -1.75M |
| EBITDA | -2.57M | -3.56M | -2.78M | -- | -- |
| EPS Basic | -0.20 | -0.52 | -0.75 | -1.29 | -0.79 |
| Normalized Basic EPS | -0.12 | -0.33 | -0.47 | -0.81 | -0.49 |
| EPS Diluted | -0.20 | -0.52 | -0.75 | -1.29 | -0.79 |
| Normalized Diluted EPS | -0.12 | -0.33 | -0.47 | -0.81 | -0.49 |
| Average Basic Shares Outstanding | 13.04M | 6.84M | 3.69M | 2.89M | 2.20M |
| Average Diluted Shares Outstanding | 13.04M | 6.84M | 3.69M | 2.89M | 2.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |